Our Work
Latham & Watkins Advises Avidity Biosciences on Oversubscribed US$400 Million Private Placement
February 29, 2024
Firm represents the biopharmaceutical company.
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), has announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing for gross proceeds of approximately US$400 million.
Latham & Watkins LLP advised Avidity Biosciences in the private placement with a corporate team lead by San Diego partners Matt Bush and Cheston Larson, with associates Nadia Patiño, Peter Simon, Derek Rogers, and Madeleine West.